Pharmacogenomics Services Market Size, Share, Growth, Analysis, 2034

(MENAFN- Straits Research) Pharmacogenomics Services Market Size & Growth Analysis

The global pharmacogenomics services market size was valued at USD 6.35 billion in 2025 and is projected to grow from USD 6.71 billion in 2026 to USD 10.41 billion by 2034, registering a CAGR of 5.65% during the forecast period (2026–2034). North America dominated the pharmacogenomics services market with a market share of 42.5% in 2025.

Pharmacogenomics services refer to specialized healthcare and laboratory services that analyze how an individual's genetic variations influence their response to medications. These services include genetic testing, drug-response analysis, and personalized treatment recommendations to help healthcare professionals select appropriate medications and dosages while minimizing adverse drug reactions.

Pharmacogenomics Services Market Key TakeawaysGlobal Market Size & GrowthGlobal Market Size (2025) USD 6.35 billionGlobal Market Size (2026) USD 6.71 billionProjected Market Size (2034) USD 10.41 billionMarket CAGR (2026–2034) 5.65%Regional Insights Largest Regional Market (2025) North America North America Market Share (2025) 42.5% Fastest-growing Region Asia-Pacific Asia-Pacific CAGR (2026–2034) 12.36%Segment Insights By Type Leading Segment Products Market Share in 2025 46.8% By Products Leading Segment Genotyping Kits Market Share in 2025 31.6% By Services Leading Segment Genetic Testing Services Market Share in 2025 58.4% By Software Leading Segment Bioinformatics Software Market Share in 2025 32.2%

Download a Free Sample To learn more about this report.

01

Preemptive Pharmacogenomic Screening

Demand for proactive medication optimization is supporting the adoption of preemptive pharmacogenomic testing across healthcare settings. These services analyze inherited genetic variations in drug-metabolizing enzymes and transporters before medication is prescribed, helping clinicians identify potential adverse reactions and differences in drug response. This trend is encouraging laboratories and healthcare providers to offer broader genetic screening panels that can guide medication decisions across multiple therapeutic areas.

02

Pharmacogenomic Data Integration in EHRs

Demand for accessible genetic insights during clinical decision-making is encouraging the integration of pharmacogenomic results into electronic health record systems. Clinical decision-support tools can interpret relevant gene-drug interactions and provide prescribing alerts when a medication may require an alternative or dosage adjustment. This development is supporting the expansion of digital pharmacogenomics services and enabling healthcare providers to incorporate genetic information into routine prescribing workflows.

Pharmacogenomics Services Market Dynamics 01

Growing Adoption in Psychiatric Care

The increasing use of pharmacogenomic testing in psychiatric care raises demand for services that help clinicians select suitable medications based on patients' genetic profiles. Genetic variations can affect how individuals metabolize antidepressants and other psychiatric drugs, leading to differences in treatment response and side effects. For example, CYP2D6 and CYP2C19 testing can help guide medication selection and dosage for patients with depression. Greater use of genetic insights in mental healthcare encourages hospitals and specialized clinics to adopt pharmacogenomic testing, supporting market demand.

02

Rising Demand for Precision Dosing in Pain Management

The need for safer and more effective pain management increases demand for pharmacogenomic services that help determine how patients respond to specific pain medications. Genetic variations in drug-metabolizing enzymes, particularly CYP2D6, can influence the effectiveness and safety of certain opioids. For example, CYP2D6 testing can help clinicians assess a patient's likely response to codeine and consider alternative treatments when needed. Growing attention to personalized pain treatment encourages healthcare providers to use pharmacogenomic testing, expanding demand for laboratory analysis and clinical interpretation services.

03

Impact Analysis of Key Drivers in Pharmacogenomics Services Market

Drivers	Market Impact
Growing Adoption in Psychiatric Care	Increasing use of pharmacogenomic testing in psychiatry supports demand for services that help clinicians select suitable medications and dosages. Genetic insights into drug metabolism can assist in managing treatment response for patients with depression and other mental health conditions.
Rising Demand for Precision Dosing in Pain Management	The need to optimize pain medication use increases demand for pharmacogenomic services that assess genetic variations affecting drug metabolism. Testing related to CYP2D6, for example, can help clinicians evaluate how patients may respond to certain opioid medications, supporting more informed prescribing decisions.
Expansion of Pharmacogenomics in Transplant Medicine	The use of pharmacogenomic testing in transplant care supports demand for services that help determine appropriate immunosuppressant dosages. Genetic variations affecting the metabolism of medicines such as tacrolimus create opportunities for specialized testing and interpretation services.
Increasing Insurance Coverage and Reimbursement	Wider insurance coverage and reimbursement for clinically relevant pharmacogenomic tests can reduce out-of-pocket costs for patients and healthcare providers. Improved affordability encourages test utilization and supports demand for laboratory testing and clinical interpretation services.
Expansion of Specialized Pharmacogenomic Laboratory Networks	The growing availability of specialized laboratories, testing platforms, and clinical interpretation capabilities improves access to pharmacogenomic services. Greater testing capacity and broader service coverage support market supply while enabling hospitals and clinics to offer testing to more patients.

01

High Cost of Pharmacogenomic Testing and Services

High costs of pharmacogenomic testing and services create financial barriers for patients and healthcare providers. Expenses related to genetic sequencing, laboratory infrastructure, specialized equipment, and result interpretation increase the overall cost of testing. These financial constraints can limit patient access, discourage routine clinical use, and slow the adoption of pharmacogenomic services.

02

Lack of Standardized Clinical Guidelines and Evidence

The lack of standardized clinical guidelines and sufficient evidence creates uncertainty in the use of pharmacogenomic results for treatment decisions. Variations in testing protocols, result interpretation, and clinical recommendations make it difficult for healthcare professionals to apply findings consistently. This uncertainty can reduce physician confidence, delay integration into routine care, and restrict market adoption.

03

Impact Analysis of Key Restraints in Pharmacogenomics Services Market

Restraints	Market Impact
High Cost of Pharmacogenomic Testing and Services	Genetic testing, sequencing technologies, data analysis, and specialized laboratory services involve substantial costs. These expenses can limit affordability for patients and discourage healthcare providers from adopting pharmacogenomic services, particularly in cost-sensitive markets.
Limited Clinical Awareness and Healthcare Professional Training	Many healthcare professionals have limited knowledge of pharmacogenomic testing and its role in treatment selection. Insufficient training and awareness can reduce test recommendations, delay integration into clinical workflows, and restrict service adoption.
Lack of Standardized Clinical Guidelines and Evidence	Variations in testing methods, interpretation standards, and clinical recommendations create uncertainty about the use of pharmacogenomic results. Limited evidence for certain gene-drug associations can make physicians cautious about incorporating these services into routine treatment decisions.
Data Privacy and Genetic Information Security Concerns	Pharmacogenomic services involve the collection and storage of sensitive genetic information. Concerns about unauthorized access, data misuse, and inadequate protection can reduce patient willingness to undergo testing and create compliance costs for service providers.
Limited Reimbursement and Insurance Coverage	Inconsistent reimbursement policies and limited insurance coverage increase out-of-pocket testing expenses. This financial burden can discourage patients and healthcare institutions from using pharmacogenomic services, restricting broader market penetration.

01

Pharmacogenomic Test Kit Development

Diagnostic companies, biotechnology firms, pharmaceutical manufacturers, and molecular testing laboratories can benefit from developing commercial pharmacogenomic test kits for hospitals and clinical laboratories. Ready-to-use kits, customized testing panels, and reagent sales create additional revenue streams, with companies such as Thermo Fisher Scientific and Illumina offering relevant genetic testing technologies.

02

Clinical Training and Education Services

Hospitals, healthcare professionals, medical universities, and diagnostic laboratories can benefit from specialized pharmacogenomic training that improves the interpretation and application of genetic test results. Service providers can generate revenue through certification programs, professional workshops, clinical consulting, and educational subscriptions, with companies such as Myriad Genetics and Genomind offering pharmacogenomic testing and related clinical support.

Pharmacogenomics Services Market Segmental AnalysisBy Type

Products accounted for the largest market share of 46.8%, supported by demand for genotyping kits, sequencing instruments, and other essential tools used in pharmacogenomic testing. Their role in enabling genetic analysis and personalized treatment selection supports their leading position in the market.

Software is projected to register the highest CAGR of 11.48%, driven by the growing need for genomic data analysis, clinical interpretation, and integration of pharmacogenomic insights into treatment decisions. Wider adoption of digital tools for personalized medicine is expected to support segment growth.

Request Customization to receive a tailored report.

By Products

Genotyping kits held the largest market share of 31.6%, driven by their essential role in identifying genetic variations associated with drug response. Their application in personalized treatment selection and routine pharmacogenomic testing supports strong demand.

Sequencing instruments are expected to record the highest CAGR of 10.41%, supported by advances in sequencing technologies and their ability to provide detailed genetic information. Growing use of comprehensive genomic analysis in precision medicine is expected to accelerate adoption.

By Services

Genetic testing services are projected to register a CAGR of 10.64%, supported by growing demand for genetic assessments that help identify variations affecting drug efficacy and safety. Their role in guiding personalized treatment decisions sustains demand across healthcare settings.

Pharmacogenomic consulting is expected to grow at a CAGR of 9.91%, driven by the need for expert interpretation of genetic test results and their application in clinical practice. Guidance on drug selection and dosage optimization supports the adoption of these services.

By Software

Bioinformatics software accounted for the largest market share of 32.2%, supported by its role in processing, analyzing, and interpreting complex genomic data. Its application across pharmacogenomic testing and research workflows reinforces its market position.

Clinical decision support system is projected to register the highest CAGR of 12.46%, driven by growing integration of genetic information into clinical treatment decisions. These systems help healthcare professionals identify suitable medications and optimize dosages based on individual genetic profiles.

By Technology

Next-generation sequencing held the largest market share of 34.7%, driven by its ability to analyze multiple genetic variations and provide comprehensive genomic information. Its broad application in pharmacogenomic testing and precision medicine supports its leading position.

Next-generation sequencing is also expected to record the highest CAGR of 11.36%, supported by improvements in sequencing accuracy, throughput, and cost efficiency. Wider use of comprehensive genetic profiling in personalized drug selection is expected to drive segment growth.

By Application

Oncology accounted for the largest market share of 28.6%, supported by the role of genetic profiling in identifying variations that influence cancer drug response. The need to select targeted therapies and improve treatment outcomes strengthens demand for pharmacogenomic applications in cancer care.

Oncology is also projected to register the highest CAGR of 11.42%, driven by the expanding use of precision oncology and genetic testing to guide treatment selection. Greater adoption of personalized cancer therapies is expected to support segment growth.

By End User

Clinical laboratories held the largest market share of 35.4%, driven by their role in conducting genetic tests, analyzing patient samples, and providing pharmacogenomic results to healthcare providers. Their established testing infrastructure supports widespread adoption of pharmacogenomic services.

Pharmaceutical companies are expected to register the highest CAGR of 10.91%, supported by the use of pharmacogenomic data in drug development, clinical trials, and personalized medicine research. Greater focus on identifying patient-specific drug responses is expected to strengthen demand from this segment.

Speak to an Analyst to discuss market opportunities.

Pharmacogenomics Services Market Regional Analysis North America Pharmacogenomics Services Market

The North America pharmacogenomics services market accounted for the dominant share of 42.5% in 2025.

U.S. Pharmacogenomics Services Market

The U.S. National Institutes of Health is supporting pharmacogenomics implementation research through projects extending to 2030, while its RePORTER programme highlights that approximately 15–20% of FDA-approved medications are affected by common genetic variations, creating scope for wider genetic testing and personalized prescribing.

Canada Pharmacogenomics Services Market

The Government of Canada's Canadian Genomics Strategy is backed by CAD 175.1 million in federal funding over seven years from 2024–25 to advance personalized medicine and genomic applications, while the Canadian Institutes of Health Research envisions pharmacogenomics becoming standard clinical practice within the next decade to guide drug dosing and reduce adverse drug interactions.

Unlock Regional Insights to access country-level data, & regional trends.

Asia Pacific Pharmacogenomics Services Market

The Asia Pacific pharmacogenomics services market is expected to grow at a CAGR of 12.36% during the forecast period 2026–2034, showcasing the fastest-growing regional market.

Japan Pharmacogenomics Services Market

Japan's AMED continues to fund genomic drug-discovery and personalized-medicine research in FY2026, including projects using whole-genome, multi-omics and clinical data to support individualized treatment, while the National Cancer Center reported that more than 100,000 patients' genomic data had been submitted to its C-CAT database by the end of FY2024, strengthening the infrastructure for wider pharmacogenomic applications.

China Pharmacogenomics Services Market

China's 2026–2030 pharmaceutical industry plan targets annual growth of at least 20% in the innovative-drug sector and aims for domestically developed first-in-class drugs to represent at least 25% of the global total by 2030, while its Healthy China 2030 strategy supports precision medicine and nationwide health-data sharing, creating opportunities for pharmacogenomic testing to guide personalized drug selection and dosing.

India Pharmacogenomics Services Market

India's GenomeIndia initiative has completed whole-genome sequencing of more than 10,000 individuals from 99 population groups and is building a biobank of 20,000 samples, with plans to develop low-cost genetic diagnostic chips, creating a foundation for population-specific pharmacogenomic testing and personalized prescriptions.

Europe Pharmacogenomics Services Market

The Europe pharmacogenomics services market accounted for the regional share of 27.4% in 2025.

U.K. Pharmacogenomics Services Market

The U.K. Government's Life Sciences Sector Plan targets more than 500,000 genomes in the Genomics England research database by 2030 and up to 5 million participants in the Our Future Health programme, while the NHS aims to expand pharmacogenomics through its Genomic Medicine Service and integrate genetic information into prescribing decisions, supporting wider adoption of personalized drug testing.

Germany Pharmacogenomics Services Market

Germany's Federal Ministry of Health launched a genome-sequencing pilot in July 2024 with a minimum five-year implementation period to integrate genomic medicine into healthcare, while the genomDE national strategy aims to establish genome sequencing as part of standard care and enable individualized treatment, creating infrastructure that can support broader pharmacogenomic testing and personalized prescribing.

Competitive landscape

The pharmacogenomics services market is moderately fragmented, with participation from established diagnostic laboratories, genomic testing companies, pharmaceutical service providers, biotechnology firms, contract research organizations, and specialized precision medicine companies. The leading players in the pharmacogenomics services market are Thermo Fisher Scientific, Admera Health, Agena Biosciences Inc., Illumina Inc., and OneOme LLC, with these five companies estimated to collectively account for approximately 25–30% of the global pharmacogenomics services market share; this is an indicative estimate, as their exact combined share is not publicly disclosed.

Established players primarily compete on testing accuracy, genetic data interpretation capabilities, laboratory infrastructure, regulatory compliance, clinical validation, test coverage, turnaround time, and partnerships with healthcare providers and pharmaceutical companies. Emerging players generally compete through advanced sequencing technologies, AI-driven genetic analysis, personalized reporting platforms, cost-effective testing services, faster sample processing, specialized gene panels, and solutions tailored to specific therapeutic areas and patient populations within the pharmacogenomics services market ecosystem.

List of Key and Emerging Players in Pharmacogenomics Services Market Thermo Fisher Scientific Inc. (U.S. Admera Health, LLC (U.S.) Agena Bioscience, Inc. (U.S.) Illumina, Inc. (U.S.) OneOme, LLC (U.S. Myriad Genetics, Inc. (U.S.) Quest Diagnostics Incorporated (U.S.) Dynamic DNA Laboratories (U.S.) Personalis, Inc. (U.S. Coriell Life Sciences (U.S.) Phamatech, Inc. (U.S.) BiogeniQ Inc. (Canada) CENTOGENE N.V. (Germany) Empire Genomics (U.S.) ViennaLab Diagnostics GmbH (Austria)Key Industry Developments January 2026 Genomind was awarded a U.S. Department of Defense contract to support the Defense Health Agency's pharmacogenomics implementation project for active-duty service members, including integration of genetic insights into military health records. September 2025 Quest Diagnostics launched an advanced pharmacogenomics service using personalized insights from Coriell Life Sciences to support medication selection and prescribing decisions across multiple clinical specialties ScopeSegmentation By Type 3

Products Services Software

By Technology 6

Next-Generation Sequencing Polymerase Chain Reaction Mass Spectrometry Microarray Gel Electrophorosis Others

By Application 7

Cardiovascular disease Infectious diseases Oncology Psychiatry Neurological diseases Pain Management and Trauma Others

By End-User 5

Hospitals Clinical Laboratories Pharmaceutical Companies Academic Research Institutions Others

Geographies Covered North America 2

U.S. Canada

Europe 8

U.K. Germany France Spain Italy Russia Nordic Benelux

APAC 7

China Korea Japan India Australia Taiwan South East Asia

Middle East and Africa 6

UAE Turkey Saudi Arabia South Africa Egypt Nigeria

LATAM 5

Brazil Mexico Argentina Chile Colombia

Competitive Coverage Thermo Fisher Scientific Inc. (U.S.) · Admera Health, LLC (U.S.) · Agena Bioscience, Inc. (U.S.) · Illumina, Inc. (U.S.) · OneOme, LLC (U.S.) Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs) The pharmacogenomics services market size is valued at USD 6.71 Billion in 2026 and is projected to reach USD 10.41 Billion by 2034, at a CAGR of 5.65% during the forecast period 2026-2034. North America dominated the market with a share of 42.5% in 2025. The leading players in this market are Thermo Fisher Scientific, Admera Health, Agena Biosciences Inc., Illunima Inc, OneOme LLC. The pharmacogenomics services market is projected to grow at a CAGR of 5.65% during the forecast period of 2026 2034.

MENAFN12112026004597010906ID1111950600